Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived off-the-shelf cellular immunotherapies, has announced its participation in two major investor conferences in September 2025.
The company will attend the 2025 Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one meetings, and will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 4 at 10:55 AM ET in New York. Webcasts of the presentations, if recorded, will be available on the company's investor relations website.
Fate Therapeutics (NASDAQ: FATE), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di immunoterapie cellulari allogeniche derivate da iPSC pronte all'uso, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
L'azienda sarà presente al 2025 Wells Fargo Healthcare Conference il 3 settembre a Boston per incontri one-to-one e parteciperà a un fireside chat al Cantor Global Healthcare Conference 2025 il 4 settembre alle 10:55 ET a New York. Se disponibili, le webcast delle presentazioni saranno pubblicate sul sito dedicato agli investitori della società.
Fate Therapeutics (NASDAQ: FATE), una compañía biofarmacéutica en fase clínica centrada en desarrollar inmunoterapias celulares off-the-shelf derivadas de iPSC, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La compañía asistirá al 2025 Wells Fargo Healthcare Conference el 3 de septiembre en Boston para reuniones one-on-one, y participará en un fireside chat en el Cantor Global Healthcare Conference 2025 el 4 de septiembre a las 10:55 AM ET en Nueva York. Las retransmisiones por web de las presentaciones, si están disponibles, se publicarán en la web de relaciones con inversores de la compañía.
Fate Therapeutics (NASDAQ: FATE)는 iPSC 유래의 기성품(off-the-shelf) 세포 면역치료제를 개발하는 임상 단계의 바이오제약회사로, 2025년 9월에 열리는 두 건의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 9월 3일 보스턴에서 열리는 2025 Wells Fargo Healthcare Conference에 1:1 미팅을 위해 참석하며, 9월 4일 오전 10시 55분(동부시간)에 뉴욕에서 열리는 Cantor Global Healthcare Conference 2025의 fireside chat에 참여할 예정입니다. 발표의 웹캐스트가 제공되는 경우 회사 투자자 관계 웹사이트에서 확인할 수 있습니다.
Fate Therapeutics (NASDAQ: FATE), une société biopharmaceutique en phase clinique spécialisée dans le développement d'immunothérapies cellulaires « off-the-shelf » dérivées d'iPSC, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société assistera au 2025 Wells Fargo Healthcare Conference le 3 septembre à Boston pour des réunions individuelles et participera à un fireside chat lors du Cantor Global Healthcare Conference 2025 le 4 septembre à 10h55 ET à New York. Les webcasts des présentations, si disponibles, seront publiés sur le site relations investisseurs de la société.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von iPSC-abgeleiteten, sofort verfügbaren (off-the-shelf) zellulären Immuntherapien konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 2025 Wells Fargo Healthcare Conference am 3. September in Boston für One-on-One-Gespräche teilnehmen und am Cantor Global Healthcare Conference 2025 am 4. September um 10:55 Uhr ET in New York in einem Fireside Chat vertreten sein. Webcasts der Präsentationen werden, sofern verfügbar, auf der Investor-Relations-Website des Unternehmens bereitgestellt.
- None.
- None.
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, announced that the Company will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference, including one-on-one meetings on Wednesday, September 3, 2025 in Boston, Massachusetts
- Cantor Global Healthcare Conference 2025, including a fireside chat at 10:55 AM ET on Thursday, September 4, 2025 in New York, New York
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
When is Fate Therapeutics (FATE) presenting at the Wells Fargo Healthcare Conference 2025?
What time is Fate Therapeutics' presentation at the Cantor Global Healthcare Conference 2025?
Where can I watch Fate Therapeutics' (FATE) investor conference presentations?
What type of company is Fate Therapeutics (FATE)?
